XtalPi Holdings (02228.HK), the 'First AI for Science Stock', Completes HK$2.65 Billion Share Placement, Becomes Global Leader in AI Pharma Fundraising

Intelligent Finance APP learned that XtalPi Holdings Limited (02228) once again demonstrated its strong appeal and efficient execution in the capital market with a textbook-level "lightning placement." On August 29, 2025, XtalPi Holdings announced that it had entered into a placement agreement with the placement agent to place up to approximately 286 million placement shares through the placement agent. According to the announcement, the funds will be used for company operations, product development, mergers and acquisitions, among others.Will explore the application of innovative financial tools such as RWA (Real World Assets) and RDA (Real Data Assets) to develop new blockchain businesses.On the same day, XtalPi Holdings Limited announced the successful completion of the pricing of a new share placement worth HK$2.65 billion.The entire process from the opening of the books to pricing was completed in less than one trading day.The placement price was set at HK$9.28 per share, representing a premium of approximately 75.8% over the IPO issue price and a premium of approximately 23.4% over the average closing price in the last 30 trading days, demonstrating the market's high recognition of its value.

It is reported that the previous placement projects of XtalPi Holdings Limited received enthusiastic market responses, with bookbuilding often being multiple times oversubscribed. This placement continued the strong momentum, achieving coverage shortly after the book was opened and attracting numerous institutions, including top-tier international sovereign funds and long-term onshore and offshore funds, to subscribe enthusiastically. The final order book was multiple times covered, and the issuance size increased by over 13% compared to the initial size. This placement marks the company's third public market financing following new share placements in January and February 2025, fully demonstrating global investors' firm confidence in the company’s future development prospects.

According to a person from the investment bank involved in this placement who revealed to Zhitong Finance, the placement included the world's largest sovereign fund – Norges (Norges Bank Investment Management). As early as 2023, its capital scale had reached $1.3 trillion.

Since its listing, XtalPi Holdings Limited has consistently focused on product iteration and commercial expansion, with operating performance showing rapid growth. In the first half of 2025, XtalPi achieved scaled profitability for the first time. Revenue from its drug discovery solutions business surged 615.2% year-over-year to RMB 435 million, while revenue from intelligent robotics solutions increased by 95.9% year-over-year to RMB 82 million. This outstanding achievement demonstratesThe Increasingly Important Role of AI in Drug and Materials Science R&D

XtalPi Holdings Limited has now become an undisputed giant in the global AI drug discovery field. As of August 27, its market value exceeded 41.2 billion Hong Kong dollars, making it the highest-valued company in Asia's AI drug discovery sector. Meanwhile, XtalPi Holdings Limited also holds the record for the largest historical financing scale in the global AI drug research and development field, having set the highest financing amount in this area. According to a research report by GoldSun Securities, since AI pharmaceuticals represent a brand-new track of technological crossover, the first breakthrough in the future could come from an AI-driven pharmaceutical company, a traditional innovative leader with deep foresight in AI, or even a new technology company outside the pharmaceutical field.

Not only that, but the company also hasStrong Cash ReservesAs of June 30, 2025, XtalPi Holdings Limited holds a cash balance of 5.308 billion yuan. Adding the amount from this new round of financing means the company now has approximately 8 billion yuan in cash reserves, which are extremely abundant. Sufficient funding has always been a strong guarantee for the company to maintain its leading position in this field. Against the backdrop of rapid global AI development and the era where cash is king, XtalPi Holdings Limited has clearly stockpiled ample resources to sustain the continuous growth of its market competitiveness.

In addition, in recent years, pharmaceutical companies have actively explored tokenized issuance based on the future revenue rights of innovative drug development. Notably,On August 6, the RWA registration platform officially launched in Hong Kong.Initiated by the Hong Kong Web3.0 Standardization Association, it will establish a full-process service system for the digitization, assetization, and financialization of RWA asset tokenization. XtalPi's AI + robotics molecular discovery platform is naturally compatible with RWA and RDA, and according to previous industry reports,XtalPi Ventures into Web3 Technology at an Opportune Time After Early Strategic LayoutXtalPi Holdings Limited plans to continuously use the proceeds from this placement for product and R&D iteration, commercial expansion, and potential acquisitions. Meanwhile, the company will also explore the use of innovative financial tools such as RWA (Real World Assets) and RDA (Real Data Assets). Through RWA, XtalPi Holdings Limited can digitally transform real-world assets such as R&D achievements and patents, enhancing asset liquidity, broadening financing channels, and injecting more funding and vitality into innovative drug development to gain a competitive edge in the industry.